{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "ELVN",
  "name": "Enliven Therapeutics, Inc.",
  "url": "https://frontierpicks.com/dossiers/ELVN/",
  "json_url": "https://frontierpicks.com/dossiers/ELVN.json",
  "status": "DORMANT",
  "current_conviction": "MEDIUM",
  "graded_conviction": null,
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "Funded single-asset CML story broadening its shareholder base: Barclays initiated Overweight $78, William Blair Outperform and Mizuho raised to $73 all on 2026-08-18, yet the 2026-08-21 close of $59.82 sits 2.1% under the $61.11 high with RSI cooled from 76.4 to 57.5. Last new clinical data was 2026-06-11; nothing dated resolves before the Q3 print.",
  "invalidation_trigger": "A weekly close below $48.50 round-trips the entire August re-rate through the July post-EHA shelf; secondary, the Q3 print (~2026-11-05, est.) restating ENABLE-2 initiation as 1H 2027 against repeated 2H 2026 guidance.",
  "catalyst_date": null,
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "oncology-immunology",
    "binary-catalyst-biotech"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Pre-revenue clinical-stage: no product revenue line, so each quarterly print is a spend-and-milestone report rather than a fundamentals check.",
    "ELVN-001 carries effectively the entire valuation; one safety or regulatory event moves the whole equity, not a segment of it.",
    "Cash, cash equivalents and marketable securities were $895.2M at 2026-06-30 with runway guided into 2030, but Phase 3 costs step R&D up from the $29.0M Q2 level.",
    "Weighted-average shares were 66.2M in Q2 2026 vs 52.1M in Q2 2025 after the 2026-06-12 offering of 8,933,334 shares at $37.50 plus pre-funded warrants.",
    "Published targets span $64-$82 after the 2026-08-18 initiations; the dispersion reflects wide model assumptions on 2L+ CML share capture.",
    "Several insiders sell under Rule 10b5-1 plans after option exercises, so individual Form 4 sales are pre-scheduled rather than discretionary."
  ],
  "body_markdown": "## Current Thesis\nThe narrative leg on offer is unchanged in substance and broader in ownership: a single-asset CML company with an FDA-agreed pivotal design, Fast Track in hand, and $895.2M of cash, cash equivalents and marketable securities as of 2026-06-30 with runway guided into 2030 (2026-08-05 Q2 release). What changed since the last note is who is publishing on it. On 2026-08-18 Barclays initiated at Overweight with a $78 target, arguing ELVN-001 \"has demonstrated differentiated efficacy from previous generation active site inhibitors\"; William Blair initiated at Outperform the same morning; Mizuho maintained Outperform and lifted its target to $73. Three fresh marks did not produce a new high. The 2026-08-21 close of $59.82 is 2.1% below the $61.11 52-week high, and RSI(14) has decayed from 76.4 at the 2026-08-07 close of $60.46 to 57.5 — the momentum extension unwound sideways rather than through a drawdown. Last new clinical information remains 2026-06-11. Nothing dated resolves inside the next 30 days.\n\n## Bull Case\n- **Design risk on the pivotal is retired.** Per the 2026-06-11 release, FDA alignment covers 80 mg once daily as the recommended Phase 3 dose, a 2L+ population (CML previously treated with one or more TKIs), and a comparator of physician's choice ATP-competitive TKI. The 2026-08-05 business update reaffirmed ENABLE-2 initiation in 2H 2026.\n- **Coverage breadth expanded on 2026-08-18, not just target levels.** Two new houses (Barclays, William Blair) joined a list that already ran Jones $70, Stifel $82, Goldman $80, Guggenheim $78 and HC Wainwright $64; Mizuho moved to $73 the same day. Every published target sits above the 2026-08-21 close.\n- **The 80 mg efficacy set held as denominators grew (2026-06-11):** 61% overall MMR, 48% MMR by 24 weeks (n=21 for the 24-week measure), 67% overall MMR in patients with one to two prior TKIs.\n- **Tolerability is the commercial wedge (2026-06-11):** 6% discontinuation for adverse events, Grade ≥3 AEs in 24% (15/62) at 80 mg, across 161 enrolled with 35-week median treatment duration.\n- **The trial is funded before it starts.** $895.2M at 2026-06-30 against a Q2 net loss of $32.5M and R&D of $29.0M; management guides runway into 2030, so Phase 3 spend does not force a raise at the current quote.\n\n## Bear Case\n- **Ten weeks with no new clinical datapoint.** Everything between 2026-06-11 and today is financial reporting, Fast Track disclosure and sell-side modelling. The August advance was produced by the 8/5 print, the 8/6 target cluster and the 8/18 initiations.\n- **The 8/18 initiations were absorbed.** Barclays' $78 was struck at roughly 31% above the 2026-08-17 close, and the stock closed 2026-08-21 at $59.82 — below the 2026-08-07 close of $60.46 and still under the $61.11 high. Fresh coverage arriving without a new high is the observable, not a verdict on it.\n- **Insiders are converting cheap paper into stock at the highs.** CMO Helen Collins exercised 5,000 options at $2.48 on 2026-08-17 and sold 3,900 at $58.3717 and 1,100 at $59.3465 under a Rule 10b5-1 plan. Director Mika Derynck exercised 87,373 options at $2.48, 27,567 at $25.28 and 23,364 at $14.85 on 2026-08-04, with a Form 144 filed the same day naming Jefferies.\n- **Q2 missed the modelled line.** EPS of $(0.49) against a $(0.40) estimate (2026-08-05), with R&D at $29.0M versus $21.5M a year earlier — before ENABLE-2 costs begin.\n- **The comparator answers a narrower question than the pitch.** Physician's choice of an ATP-competitive TKI is not asciminib, so a positive ENABLE-2 leaves the head-to-head against Scemblix — the franchise the share-capture case targets — unresolved.\n- **Share count is 27% higher year over year.** Weighted-average shares were 66.2M in Q2 2026 versus 52.1M in Q2 2025, following the 2026-06-12 offering of 8,933,334 shares at $37.50 plus pre-funded warrants.\n\n## Setup & Price Structure\nThe narrative is **maturing**. The story is well known and still working, but the marginal flow is moderating. Dating that: the last new clinical information is 2026-06-11; the 8/6 target cluster and the 8/18 initiations both landed without carrying price through $61.11; and RSI(14) fell from 76.4 (2026-08-07) to 57.5 (2026-08-21) while the close moved only from $60.46 to $59.82. That is a two-week consolidation directly under the high rather than distribution — the shares are up 44.0% over three months and 2.1% off the 52-week high. Reference points visible in public prints: the CMO's 10b5-1 sales cleared at $58.3717 and $59.3465 on 2026-08-17, the 2026-06-12 offering priced at $37.50, and OrbiMed's June exits printed near $45. Crowding evidence to weigh: an unusually dense cluster of initiations and raises inside 13 days (8/6 and 8/18), a published target band of $64–$82 that now brackets the quote almost entirely to the upside, insider option-exercise-and-sell activity at the highs, and no earnings date inside 30 days to force a re-mark either way. The structural work is the $57–$61 area holding as a shelf; below that, the July post-EHA range around $48.50 is the level where the entire August re-rate is given back.\n\n## Catalyst Calendar (next 30 days)\n- **No confirmed dated company event between 2026-08-22 and 2026-09-21.** The named items sit at or beyond the boundary.\n- **~2026-09-30 (est.)** — End-of-Phase 2 meeting with FDA, guided to Q3 2026 (2026-06-11, reaffirmed 2026-08-05). Company practice has been to disclose the outcome at the next print rather than in real time, so the calendar quarter closing without news is itself ambiguous.\n- **~2026-10-31 (est.)** — First appearance of an ENABLE-2 record or site-activation update on ClinicalTrials.gov would be the earliest independent confirmation that initiation is tracking to 2H 2026.\n- **~2026-11-05 (est.)** — Q3 2026 results and business update: where initiation timing either holds or slips, and where the first Phase 3 R&D step-up shows against the $895.2M balance.\n- **~2026-12-31 (est.)** — Outer edge of the repeated 2H 2026 ENABLE-2 initiation guidance.\n\n## What Would Change Our Mind\nThe structure that matters is the shelf built between the 2026-08-05 print and the 2026-08-18 initiations. If the 2H 2026 initiation guidance is restated as 1H 2027 at the Q3 print (~2026-11-05, est.), or the Q3 quarter closes with no disclosed End-of-Phase 2 outcome, the name carries no dated fundamental event into 2027 and the $64–$82 target band loses its scaffolding. On price, a weekly close below $48.50 round-trips the August re-rate through the July post-EHA shelf and would mark the sell-side re-marking cycle as fully retraced. On the other side, the read strengthens if an ENABLE-2 registration posts publicly before the Q3 print, or if a subsequent data update expands the 80 mg 24-week MMR denominator beyond n=21 without the 61%/48% figures deteriorating. A further target cut following Guggenheim's 2026-08-06 move to $78 — particularly from one of the 8/18 initiators — would say the re-rate is two-way.\n\n## Correlation Notes\n- Single-asset exposure: ELVN-001 carries effectively the whole equity, so company-specific safety or regulatory news moves the entire market cap rather than a segment.\n- Competitive read-through runs through Novartis and asciminib (Scemblix). A Novartis readout narrowing the tolerability gap or expanding asciminib into the 2L+ population ENABLE-2 targets is the single largest exogenous risk to the wedge argument.\n- Hematology congress windows (ASCO, EHA, ASH) cluster clinical-stage oncology names into one concentrated exposure; the 2026-06-11 move was inside such a window.\n- Pre-revenue, long-duration cash flows make the name sensitive to biotech-index beta and rate direction independent of ELVN-001 news; with runway guided into 2030, financing sensitivity to a closed window is lower than for peers without a 2026 raise.",
  "first_seen": "2026-04-19",
  "last_analyzed": "2026-08-22T08:20:37+00:00",
  "last_synthesized": "2026-08-22",
  "last_update_source": "watchlist_research",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}